Monica Michele Carrozzo McSherry: Converging Pathways Between Homocysteine and Cholesterol in Cardiovascular Risk
Monica Michele Carrozzo McSherry, Registered Nutritional Therapist at Healthmatters Health Store, Freelance Writer at Dulwich Nutrition, shared a post on LinkedIn:
“Homocysteine (Hcy), a sulfur-containing amino acid derived from methionine metabolism, is remethylated to methionine via folate and vitamin B12 or transsulfurated to cystathionine via vitamin B6.
Elevated plasma Hcy, or hyperhomocysteinemia, is a recognized risk factor for atherosclerosis, primarily through endothelial dysfunction, oxidative stress, and inflammation.
Hcy promotes reactive oxygen species formation, reduces nitric oxide bioavailability, and stimulates pro-inflammatory pathways, accelerating vascular injury.
Cholesterol, particularly LDL-C, drives atherogenesis through subendothelial deposition, oxidation, and foam cell formation, whereas HDL-C facilitates reverse cholesterol transport and vascular protection.
Evidence indicates that hyperhomocysteinemia interacts with lipid metabolism by increasing LDL oxidation, impairing HDL function, and modulating hepatic cholesterol synthesis.
Oxidized LDL generated under elevated Hcy conditions is highly atherogenic, while inhibition of HDL-associated paraoxonase-1 reduces antioxidant defense, compounding vascular risk.
Genetic variants affecting homocysteine metabolism, such as MTHFR C677T, associate with elevated Hcy and altered lipid profiles, highlighting a combined genetic predisposition to cardiovascular disease.
Epidemiological data suggest additive risk when hyperhomocysteinemia coexists with dyslipidemia.
While B-vitamin supplementation lowers Hcy levels, effects on lipid profiles and cardiovascular outcomes are inconsistent, reflecting complex interactions involving oxidative stress, endothelial repair, and lipid oxidation.
In summary, homocysteine and cholesterol are intertwined modulators of cardiovascular risk.
Hyperhomocysteinemia exacerbates LDL oxidation and HDL dysfunction, potentiating atherogenesis.
Beyond lipid-lowering therapies, nutritional strategies targeting Hcy through folate, B12, and B6 may provide complementary cardiovascular protection, particularly in genetically susceptible populations.
Future research should clarify the mechanistic crosstalk and therapeutic implications of the homocysteine-cholesterol axis.”
Stay updated with Hemostasis Today.
-
May 7, 2026, 07:02Ana Cláudia de Souza: NeuroLeadership, Management and Behavioural Insights in Stroke Care from ESOC 2026
-
May 7, 2026, 07:00Maxime Dely: Just 60 Minutes of Our Time to Help a Patient We Will Never Meet
-
May 7, 2026, 06:37Anagha Kulkarni: Insights and A Prize from ISBMT Annual Conference 2026
-
May 7, 2026, 06:37Neelmani Singh: Why Iron Deficiency Is a Brain Health Issue
-
May 7, 2026, 06:25Vivek Sinha: The Science Behind a CBC Test
-
May 7, 2026, 06:17Emily Brown: Honor to Represent Hemophilia of Georgia at 2026 World Federation of Hemophilia Congress
-
May 7, 2026, 06:08Abdelaziz Fahem: INNOVHEM Reports a New Direct Method for Evaluating Hemolytic Anemia
-
May 7, 2026, 06:02Derick Rugenga: Every Person Living with Haemophilia Deserves to Live Without Fear
-
May 7, 2026, 05:56Ritika Jankar: Powering the Future of Precision Diagnostics